Allergan CEO, fresh off one deal, sets sights on others

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/4/2026

1. LULU
2. ZS
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to Allergan CEO, fresh off one deal, sets sights on others

Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale

July 28, 2015 9:13 AM EDT

Canaccord Genuity reiterated a Buy rating on Allergen (NYSE: AGN), and raised the price target to $396.00 (from $352.00), following the announced sale of its generics unit to Teva (NYSE: TEVA). Teva will acquire the unit for $40.5B.... More

Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement

July 28, 2015 8:19 AM EDT

Allergan (NYSE: AGN)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 (from $354.00), following this morning's announcement that TEVA will be acquiring AGNs Gx biz for $40.5B. Analyst Jason Gerberry views TEVA (OP) as the most suitable owner for the AGN's Gx assets.

Gerberry... More

Allergan (AGN), KYTHERA Biopharma (KYTH) Announce Early HSR Act Termination in Proposed Merger

July 27, 2015 4:46 PM EDT

Allergan (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Allergan's... More